Engineered Promoter for Cell-State Specific Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies lack the ability to regulate transgene expression in a cell-type or cell-state dependent manner, which is crucial for effectively treating genetic disorders characterized by differential gene expression in healthy and diseased cells.
Innovation Solution
A recombinant transcription factor binding polynucleotide and a promoter system are developed, where the polynucleotide binds to specific transcription factors more highly expressed in target cells, and the promoter is engineered to control the transcription level of a payload sequence, ensuring cell-type or cell-state specific expression of therapeutic proteins or nucleotides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgene expression is delivered into individuals for treatment of genetic disorders, then therapeutic effect is improved, but lack of cell-type or cell-state specific regulation results in detrimental side effects
Solution Approach 1:
The promoter is engineered with cell-type or cell-state specific transcription factor binding sites, creating local regulatory elements that enable selective gene expression in target cells. This allows the transgene to be expressed only in specific cell populations (e.g., cells expressing mutant MeCP2) while remaining silent in other cells, thereby achieving therapeutic effect in diseased cells without causing detrimental side effects in healthy cells
Solution Approach 2:
The invention modifies the promoter sequence by incorporating specific transcription factor binding sites that respond to cell-state parameters. By changing the promoter's nucleotide sequence to include binding sites for transcription factors differentially expressed in target cells, the system achieves conditional gene expression based on cellular parameters such as mutation status or cell type, enabling precise spatial and temporal control of therapeutic gene expression
2Measurement precision
If transgene expression is regulated in a cell-type or cell-state dependent manner, then specificity is improved, but promoter engineering complexity increases
Solution Approach 1:
The promoter is segmented into functional modules: a core promoter region and one or more transcription factor binding sites. This modular design allows for systematic engineering where specific binding sites can be added or removed to target different cell types or states without redesigning the entire promoter, thereby managing complexity while achieving high specificity
Solution Approach 2:
The engineered promoter system uses universal transcription factor binding site motifs that can be combined in different configurations to target various cell types or states. By creating a library of binding site sequences that can be mixed and matched, the system achieves multi-functionality where the same promoter engineering approach can be applied to target different cellular contexts, reducing overall system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted and controlled expression of therapeutic proteins or nucleotides in diseased cells, such as those with mutant MeCP2 protein, while minimizing expression in healthy cells, thereby treating genetic disorders like Rett syndrome with enhanced specificity and efficacy.
Implementation Method 1
the polynucleotide binds to specific transcription factors more highly expressed in target cells
Data Source
AI summary
Described herein are compositions comprising polynucleotides encoding for cell state specific transcription of a transgene. A polynucleotide may comprise a promoter that is engineered to promote cell state-specific transcription of a payload (e.g., a transgene). Also described herein are methods of treating, preventing, or ameliorating a disease or condition by delivering a polynucleotide to a cell of a subject and transcribing a transgene in a cell state-specific manner.